|
NOL11 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.77770000001176E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.76902999999839E-05 |
| Normal-vs-Stage2 |
1.599940E-03 |
| Normal-vs-Stage3 |
3.46620000035713E-07 |
| Normal-vs-Stage4 |
1.76740000412678E-09 |
| Stage1-vs-Stage2 |
7.868600E-01 |
| Stage1-vs-Stage3 |
2.048400E-01 |
| Stage1-vs-Stage4 |
4.095000E-03 |
| Stage2-vs-Stage3 |
2.674800E-01 |
| Stage2-vs-Stage4 |
2.950400E-02 |
| Stage3-vs-Stage4 |
1.603370E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.95129999994259E-07 |
| Normal-vs-AfricanAmerican |
4.855200E-03 |
| Normal-vs-Asian |
6.542200E-03 |
| Caucasian-vs-AfricanAmerican |
6.231200E-01 |
| Caucasian-vs-Asian |
1.944970E-01 |
| AfricanAmerican-vs-Asian |
6.877200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.03810000040561E-07 |
| Normal-vs-Female |
1.88189999994481E-06 |
| Male-vs-Female |
2.115800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.99149999999505E-05 |
| Normal-vs-Age(41-60Yrs) |
1.0073999999749E-06 |
| Normal-vs-Age(61-80Yrs) |
1.46890000052302E-07 |
| Normal-vs-Age(81-100Yrs) |
6.123800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.259200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.532380E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.154800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.105600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.961200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.864600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.686200E-02 |
| Classical-VS-Follicular |
2.016200E-02 |
| Classical-VS-Other |
3.504400E-01 |
| Classical-VS-Normal |
2.41279999999566E-05 |
| Tall-VS-Follicular |
9.334600E-01 |
| Tall-VS-Other |
9.373000E-01 |
| Tall-VS-Normal |
2.25689999999723E-05 |
| Follicular-VS-Other |
9.074600E-01 |
| Follicular-VS-Normal |
1.39190000003619E-06 |
| Other-VS-Normal |
1.418310E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.43130000005176E-06 |
| Normal-vs-N1 |
2.00320000032228E-07 |
| N0-vs-N1 |
1.038030E-01 |
|
|
